PUBLISHER: SkyQuest | PRODUCT CODE: 1533647
PUBLISHER: SkyQuest | PRODUCT CODE: 1533647
Global Biosimilars Market size was valued at around USD 23.45 billion in 2022 and is expected to rise from USD 27.30 billion in 2023 to reach a value of USD 92 Billion by 2031, at a CAGR of 16.4% over the forecast period (2024-2031).
The biosimilars market is poised for significant growth due to the impending expiration of key biological patents and the increasing need to reduce healthcare costs. As patents for many major biologic drugs expire, opportunities are emerging in therapeutic areas such as oncology, immunology, and endocrinology. Regulatory bodies are supporting the adoption of biosimilars by implementing faster approval processes and substitution policies. The European Union, with its robust regulatory framework, has led the way in adopting biosimilars, achieving higher adoption rates compared to other regions. Despite these opportunities, the biosimilars market faces several challenges. High capital investment required for the development and manufacturing of biosimilars, coupled with stringent regulatory requirements, can deter smaller companies from entering the market. The need for extensive, costly clinical trials to prove similarity further complicates the situation. Additionally, the established brand loyalty and trust in original biologics pose significant barriers. To address these issues, biosimilar manufacturers are forming strategic alliances and partnerships to leverage existing market presence and distribution networks. The acceptance of biosimilars among physicians and patients is also crucial for market growth and competition. While the potential in the biosimilars market is substantial, further research and regulatory adjustments are needed to foster its expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biosimilars Market Segmental Analysis
The biosimilars market is segmented into Drug Type, Indication, and region. Based on Drug Type, the market is segmented into Monocional Antibodies (Infliximab, Trastuzumab, Rituximab, Adalimumab, and Others), Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Anticoagulants, and Others. Based on Indication, the market is segmented into Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders, Growth Hormones Deficiency, Infectious Diseases, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.
Drivers of the Global Biosimilars Market
The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the growth of the biosimilars market, as there is an increasing demand for effective and cost-efficient treatments. Analysis indicates that the U.S. population aged 50 and older is expected to grow by 61.11%, from 137.25 million in 2020 to 221.13 million by 2050. During the same period, the number of individuals in this age group with at least one chronic disease is projected to nearly double, increasing by 99.5%, from 71.52 million in 2020 to 142.66 million by 2050. This significant rise in chronic disease prevalence is expected to drive demand for biosimilars, further fueling market expansion.
Restraints in the Global Biosimilars Market
The biosimilars industry faces significant challenges due to the diverse and stringent regulations across different countries, which pose substantial obstacles for companies. The lack of regulatory harmonization leads to a complex and time-consuming process, often delaying market entry and increasing development costs. Companies must navigate varying requirements from different regulatory bodies, including extensive clinical trials and detailed analytical characterization. This fragmented approach results in duplicated efforts and high compliance costs, particularly disadvantaging smaller firms. Additionally, frequent changes in policies and regulations contribute to uncertainty and extend the approval process. As a result, these regulatory hurdles significantly hinder the biosimilars industry's ability to introduce new products more quickly and cost-effectively.
Market Trends of the Global Biosimilars Market
If patients are the primary beneficiaries, then reduced prices for biosimilars will significantly boost global demand. Recent trends indicate that manufacturers are focusing on substantial cost reductions in emerging biosimilar markets. This trend is expected to persist throughout the forecast period, contributing to the growth of the global biosimilars market. Additionally, biosimilar manufacturers are likely to explore different production volumes and strategies. The ability to produce multiple biosimilar medications at a single facility may offer considerable advantages, enhancing value for manufacturers and supporting market expansion over time.